NASDAQ$BCPC
Balchem Corporation · Q3 2023 earnings
Q3 2023 earnings · · Investor relations
Briefing
Balchem reported third quarter sales with increased net earnings and adjusted EBITDA.
Balchem Corporation reported a decrease in net sales but an increase in net earnings and adjusted EBITDA for the third quarter of 2023. The company's Human Nutrition & Health segment achieved record quarterly sales and earnings from operations.
- Net sales were $229.9 million, a decrease of 5.9% compared to the prior year.
- Adjusted EBITDA was a record $59.9 million, an increase of 11.4% from the prior year.
- GAAP net earnings were $29.1 million, an increase of 15.2% from the prior year.
- Cash flows from operations were $46.5 million, with free cash flow of $38.2 million.
Headline financials
Revenue & EPS history
Balchem · Revenue · Quarterly
$230M
Revenue by segment
Balchem · $228M total across 3 segments · Q3 2023
- Human Nutrition & Health$144M+1.3%63.2%
- Animal Nutrition & Health$53.9M-17.8%23.6%
- Specialty Products$30M+1.2%13.1%
Forward guidance
The broader economic outlook and market demand still remain volatile, and volume demand patterns have not yet fully normalized, but Balchem continues to show its ability to perform in this uncertain market environment and they believe they are well positioned to benefit as the market recovers more broadly.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2023
+0.0%
Avg return
Earnings day
-0.1%
Avg return
5 days after
+0.9%
Avg return
30 days after
52%
34 / 65 earnings
Positive
+25.0%
Q1 2014
Best reaction
-16.3%
Q2 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -6.8% | -7.0% | -9.7% | |
| Q4 2025 | -2.3% | +2.6% | -7.4% | |
| Q3 2025 | +4.1% | +3.9% | +1.3% | |
| Q1 2025 | -2.6% | -1.5% | +4.8% | |
| Q4 2024 | +1.5% | +7.0% | -0.1% | |
| Q3 2024 | +2.8% | +1.6% | +9.8% | |
| Q2 2024 | +3.9% | +1.5% | -1.2% | |
| Q1 2024 | -1.8% | -3.0% | -8.8% | |
| Q4 2023 | +7.4% | +5.0% | +6.8% | |
| Q3 2023 | -5.0% | -4.1% | +1.1% | |
| Q2 2023 | +4.8% | +5.0% | +7.1% | |
| Q1 2023 | +1.7% | +0.5% | +5.2% | |
| Q4 2022 | -2.0% | -0.2% | -7.7% | |
| Q3 2022 | -0.6% | -0.5% | +5.4% | |
| Q2 2022 | -5.2% | -6.6% | +2.3% | |
| Q1 2022 | +1.6% | -0.9% | -10.5% | |
| Q4 2021 | +1.0% | -0.7% | +1.2% | |
| Q3 2021 | -0.8% | +2.3% | +7.9% | |
| Q2 2021 | -0.8% | -2.5% | +2.7% | |
| Q1 2021 | -0.2% | -0.1% | +0.5% | |
| Q4 2020 | +5.4% | +6.4% | +10.7% | |
| Q3 2020 | -1.7% | -0.5% | +3.3% | |
| Q2 2020 | +4.6% | +4.7% | +0.3% | |
| Q1 2020 | -5.4% | -3.9% | -9.3% | |
| Q4 2019 | -10.7% | -13.3% | -15.9% | |
| Q3 2019 | +2.9% | +1.2% | -0.8% | |
| Q2 2019 | -16.3% | -15.9% | -13.5% | |
| Q1 2019 | +1.1% | +4.0% | +9.4% | |
| Q4 2018 | +8.0% | +12.4% | +10.7% | |
| Q3 2018 | -4.9% | -4.9% | -13.7% | |
| Q2 2018 | +1.1% | +1.3% | +10.1% | |
| Q1 2018 | -1.3% | +2.2% | +7.9% | |
| Q4 2017 | +2.3% | +5.9% | +8.6% | |
| Q3 2017 | +1.0% | -0.7% | +1.3% | |
| Q2 2017 | -2.6% | -3.9% | -1.8% | |
| Q1 2017 | -3.3% | -5.3% | -1.8% | |
| Q4 2016 | +5.2% | +2.2% | -2.5% | |
| Q3 2016 | -4.5% | +0.8% | +12.3% | |
| Q2 2016 | +1.3% | +2.0% | +8.7% | |
| Q1 2016 | +0.3% | — | — | |
| Q4 2015 | -0.4% | — | — | |
| Q3 2015 | -2.0% | — | — | |
| Q2 2015 | +5.2% | — | — | |
| Q1 2015 | -0.5% | — | — | |
| Q4 2014 | -3.4% | — | — | |
| Q3 2014 | +6.7% | — | — | |
| Q2 2014 | +2.5% | — | — | |
| Q1 2014 | +25.0% | — | — | |
| Q4 2013 | +0.4% | — | — | |
| Q3 2013 | -4.9% | — | — | |
| Q2 2013 | +1.3% | — | — | |
| Q1 2013 | -2.3% | — | — | |
| Q4 2012 | +0.8% | — | — | |
| Q3 2012 | -10.5% | — | — | |
| Q2 2012 | +5.9% | — | — | |
| Q1 2011 | +2.1% | — | — | |
| Q4 2011 | +2.1% | — | — | |
| Q1 2012 | +2.4% | — | — | |
| Q1 2010 | -4.1% | — | — | |
| Q4 2009 | -4.1% | — | — | |
| Q3 2010 | -3.2% | — | — | |
| Q3 2011 | -3.2% | — | — | |
| Q2 2011 | +1.0% | — | — | |
| Q4 2010 | +1.0% | — | — | |
| Q2 2010 | +1.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro